Результаты поиска

Waldenström macroglobulinemia: clinical and immunological aspects, natural history, cell of origin, and emerging mouse models.

Waldenström macroglobulinemia (WM) is a rare and currently incurable neoplasm of IgM-expressing B-lymphocytes that is characterized by the occurrence of a monoclonal IgM (mIgM) paraprotein in blood serum and the infiltration of the hematopoietic bone marrow with malignant lymphoplasmacytic cells. The symptoms of patients with WM can be attributed to the extent and tissue sites of tumor cell infiltration and the magnitude and immunological specificity of the paraprotein. WM presents fascinating clues on neoplastic B-cell development, including the recent discovery of a specific gain-of-function

Совпадение в полном тексте источника
… It usually consists of alkylating agents (chlorambucil, cyclophosphamide, and melphalan), nucleoside analogues (cladribine and fludarabine), proteasome inhibitors (bortezomib), dexamethasone, and monoclonal antibody to CD20 (rituximab). …

Management of Acute Myeloid Leukemia: Current Treatment Options and Future Perspectives.

Treatment of acute myeloid leukemia (AML) has improved in recent years and several new therapeutic options have been approved. Most of them include mutation-specific approaches (e.g., gilteritinib for AML patients with activating FLT3 mutations), or are restricted to such defined AML subgroups, such as AML-MRC (AML with myeloid-related changes) or therapy-related AML (CPX-351). With this review, we aim to present a comprehensive overview of current AML therapy according to the evolved spectrum of recently approved treatment strategies. We address several aspects of combined epigenetic therapy

Совпадение в полном тексте источника
… Additionally, phase I trials combining venetoclax with frontline 7 + 3 daunorubicin/cytarabine based induction treatment ( NCT03709758 ) or a phase II trial evaluating venetoclax, cladribine, AZA and LDAC combination for previously untreated AML patients in frontline ( NCT03586609 ) will further yield …

Смолдинг нейроинфламмации в прогрессивном множественном склерозе: механизмы, визуальные биомаркеры и терапевтические возможности.

Прогрессивный множественный склероз (MS) по-прежнему является серьезной терапевтической проблемой, поскольку инвалидность часто продолжает накапливаться, несмотря на эффективный контроль за рецидивами и новыми головными провокационными повреждениями. Эта диссоциация говорит о том, что прогресс определяется не только острым воспалением, но и отдельным процессом, который все чаще называется задушающим нейро-воспалением. Последние данные подтверждают, что хронические активные повреждения являются важным, но не эксклюзивным патологическим субстратом этого процесса. Эти повреждения характеризуются

Dermatologic conditions in women receiving systemic cancer therapy.

As advances in cancer therapies have improved cancer-related survival, novel therapeutics have also introduced a variety of dermatologic toxicities, and an increased number of patients are living with these sequalae. Women with cancer in particular experience a spectrum of dermatologic conditions that affect their skin, hair, nail, and mucosal surfaces. Studies have shown that these toxic effects can significantly affect quality of life and alter a woman's self-image, cultural identity, femininity, sexuality, and mental health. In severe instances, dermatologic toxicities may even disrupt canc

Совпадение в полном тексте источника
… Oncologic indication Traditional chemotherapy Antimetabolites | 5-fluorouracil | Gastrointestinal, breast, pancreatic | Capecitabine | Gastrointestinal, breast, pancreatic | Gemcitabine | Bladder, pancreatic, ovarian, breast, non-small cell lung | Cytarabine | AML, ALL, CML, non-Hodgkin's lymphoma | Cladribine …

Targeting epigenetic methylation: emerging diagnosis and therapeutic strategies in cancer.

Epigenetics shapes all aspects of cancer occurrence and progression. Among them, chromatin methylation is a particularly important regulator of oncogenic processes. The dynamic shifts in methylation can influence the development or death of tumor cells. In the therapeutic context, effectively targeting and modulating DNA, RNA, and histone methylation brings promise for the early detection, prognostic assessment, and treatment of cancer. In particular, novel methylation inhibitors or modulators powerfully kill tumor cells or improve existing therapeutic strategies through different signaling pa

Совпадение в полном тексте источника
… NCT03525795 EZH2-1/PD1 inhibitors Valemetostat/Ipilimumab Metastatic aggressive variant prostate, urothelial, and renal cell carcinomas I, 2020 NCT04388852 EZH2/PDL1-TGFβ inhibitors SHR2554/SHR1701 Advanced solid tumors and B-cell lymphomas I/II, 2020 NCT04407741 DNMT inhibitor/Chemotherapy Guadecitabine/Cladribine … inhibitors | Valemetostat/Ipilimumab | Metastatic aggressive variant prostate, urothelial, and renal cell carcinomas | I, 2020 | NCT04388852 EZH2/PDL1-TGFβ inhibitors | SHR2554/SHR1701 | Advanced solid tumors and B-cell lymphomas | I/II, 2020 | NCT04407741 DNMT inhibitor/Chemotherapy | Guadecitabine/Cladribine …

The Clinical Application of Ozonetherapy

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Determining Risk Factors Associated with Cardiovascular Complications in Patients with Acute Leukemia: A Systematic Review.

BackgroundPatients with acute leukemia (AL) are at heightened risk of cardiovascular complications due to both disease-related and treatment-related factors. These complications include heart failure, arrhythmias, myocardial infarction, and thromboembolic events which may significantly impact morbidity and mortality.ObjectiveTo identify the risk factors contributing to cardiovascular complications in patients with acute leukemia.MethodsThis systematic review was conducted according to the PRISMA reporting guideline. Multiple databases including PubMed, Scopus, IEEE Xplore, the Cochrane Library

Совпадение в полном тексте источника
… Additionally, complications from AL treatments such as chemotherapy with drugs like anthracyclines (e.g., doxorubicin, daunorubicin, idarubicin, mitoxantrone), alkylating agents (e.g., cyclophosphamide, busulfan, melphalan), antimetabolites (e.g., cytarabine, fludarabine, cladribine, clofarabine, azacitidine …

Mechanisms of Chemotherapy-Induced Neurotoxicity.

Since the first clinical trials conducted after World War II, chemotherapeutic drugs have been extensively used in the clinic as the main cancer treatment either alone or as an adjuvant therapy before and after surgery. Although the use of chemotherapeutic drugs improved the survival of cancer patients, these drugs are notorious for causing many severe side effects that significantly reduce the efficacy of anti-cancer treatment and patients' quality of life. Many widely used chemotherapy drugs including platinum-based agents, taxanes, vinca alkaloids, proteasome inhibitors, and thalidomide ana

Совпадение в полном тексте источника
… , catumaxumab, cetuximab, elotuzumab, enfortumab vedotin-ejfv, gemtuzumab ozogamicin, inotuzumab ozogamicin, moxetumomab pasudotox, necitumumab, panitumumab, tagraxofusp-rzs, tisagenlecleucel, temsirolimus, trastuzumab-emtansine Minimal (<10%) | Cytotoxic agents | Bleomycin, 2-chlorodeoxyadenosine, cladribine …

Advances in Oncohematology Immunotherapy: Monoclonal Antibodies and CAR T-Cell Therapies.

The role of immunotherapy in oncohematology is well established. Monoclonal antibodies have undergone substantial development in recent years, targeting a wide range of molecules (including surface antigens, immune checkpoints, and cytokines) and have demonstrated clinical utility across various hematologic malignancies, including leukemias, lymphomas, and myelomas. The emergence of advanced therapy medicinal products (ATMPs), particularly chimeric antigen receptor (CAR) T cells, has provided an additional and promising therapeutic option. This rapidly evolving field continues to expand therap

Совпадение в полном тексте источника
… Results from a phase I study evaluating [ 225 Ac]Ac-lintuzumab combined with CLAG-M (cladribine + cytarabine + G-CSF + mitoxantrone) salvage therapy in R/R AML showed a composite complete remission (CRc) rate (CR/CRi) of 56.6% overall, with MRD negativity achieved in 8 of 12 responders [ 51 ]. 2.12. …

Radiometals in Imaging and Therapy: Highlighting Two Decades of Research.

The present article highlights the important progress made in the last two decades in the fields of molecular imaging and radionuclide therapy. Advancements in radiometal-based positron emission tomography, single photon emission computerized tomography, and radionuclide therapy are illustrated in terms of their production routes and ease of radiolabeling. Applications in clinical diagnostic and radionuclide therapy are considered, including human studies under clinical trials; their current stages of clinical translations and findings are summarized. Because the metalloid astatine is used for

Совпадение в полном тексте источника
… Motivated by the initial findings, several clinical trials (phase I/II), including a dose-escalation study of [ 225 Ac]Ac-lintuzumab combined with low-dose chemotherapeutic drugs (e.g., mitoxantrone, cladribine), have been initiated ( NCT03867682 [ 258 ]). …

Расширение горизонта: потенциальное применение элементов ЦАР-Т сверх нынешних показателей.

Проектирование иммунных клеток для лечения гематологических заболеваний стало одним из основных направлений исследований с тех пор, как в B-ALL были достигнуты первые заметные успехи в лечении CAR-T-клеток. В настоящее время можно лечить несколько заболеваний в условиях высокой терапии или рецидива. В настоящее время для острого лимфоболического лейкемии (ALL), диффузной лимфомы B-клеток (DLBCL), лимфомы мантичной клетки (MCL), множественной миеломы (MM) и фолликулярной лимфомы (FL) утвержден ряд методов лечения CD19- или BCMA-клеток. Применение этих методов значительно улучшило результативнос

Совпадение в полном тексте источника
… Both diseases can be controlled through established therapy regimens including cladribine and pentostatine as first-line therapies. More than 95% of patients can be treated adequately with these therapies ( 343 ). …

Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy.

Acute myeloid leukemia (AML) is the most common form of acute leukemia in adults and the second most common form of acute leukemia in children. Despite this, very little improvement in survival rates has been achieved over the past few decades. This is partially due to the heterogeneity of AML and the need for more targeted therapeutics than the traditional cytotoxic chemotherapies that have been a mainstay in therapy for the past 50 years. In the past 20 years, research has been diversifying the approach to treating AML by investigating molecular pathways uniquely relevant to AML cell prolife

Совпадение в полном тексте источника
… In a phase II clinical trial, a combination of CLAG (cladribine, cytarabine, granulocyte colony-stimulating factor (G-CSF)) regimen and imatinib mesylate was investigated in patients with R/R AML. …

CAR-T cell therapy for cancer: current challenges and future directions.

Chimeric antigen receptor T (CAR-T) cell therapies have transformed the treatment of relapsed/refractory (R/R) B-cell malignancies and multiple myeloma by redirecting activated T cells to CD19- or BCMA-expressing tumor cells. However, this approach has yet to be approved for acute myeloid leukemia (AML), the most common acute leukemia in adults and the elderly. Simultaneously, CAR-T cell therapies continue to face significant challenges in the treatment of solid tumors. The primary challenge in developing CAR-T cell therapies for AML is the absence of an ideal target antigen that is both effec

Advances in the delivery of anticancer drugs by nanoparticles and chitosan-based nanoparticles.

Cancer is the leading cause of death globally, and conventional treatments have limited efficacy with severe side effects. The use of nanotechnology has the potential to reduce the side effects of drugs by creating efficient and controlled anticancer drug delivery systems. Nanoparticles (NPs) used as drug carriers offer several advantages, including enhanced drug protection, biodistribution, selectivity and, pharmacokinetics. Therefore, this review is devoted to various organic (lipid, polymeric) as well as inorganic nanoparticles based on different building units and providing a wide range of

Совпадение в полном тексте источника
… Antimetabolites may be grouped into several classes: pyrimidine antagonists (cytarabine, 5-fluorouracil (5-FU), gemcitabine, and capecitabine), purine antagonists (fludarabine), purine analogs (6-mercaptopurine, azathioprine, and cladribine), antifolates (MTX, pemetrexed, and pralatrexate), and ribonucleotide …

Семья гистона деацетилазы в здравии и болезни.

Классические деацетилазы, включая классы I, II и IV, в зависимости от цинка, повсеместно присутствуют у млекопитающих и играют жизненно важную роль в многочисленных биологических процессах. На сегодняшний день eleven Были выявлены члены &lt; &lt; хисттон деацетилаза &gt; &gt; , а именно &lt; &lt; хиттон деацетилаза &gt; &gt; . 1 через гистонную деацетилазу 11. Растущий объем данных подчеркивает важнейшую роль этих гистоновых деацетилазов как в физиологических, так и патологических условиях. В частности, эти гистонные деацетилазы участвуют в различных клеточных процессах, включая воспаление, ме

Резюме книги для 27th Конгресс Европейской ассоциации гематологии

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Azathioprine for people with multiple sclerosis.

BackgroundMultiple sclerosis (MS) is an immune-mediated, chronic, inflammatory demyelinating disease of the central nervous system, impacting around 2.8 million people worldwide. Characterised by recurrent relapses or progression, or both, it represents a substantial global health burden, affecting people, predominantly women, at a young age (the mean age of diagnosis is 32 years). Azathioprine is used to treat chronic inflammatory and autoimmune diseases, and it is used in clinical practice as an off-label intervention for MS, especially where access to on-label disease-modifying treatments (

Совпадение в полном тексте источника
… Recent approvals of ocrelizumab, siponimod, ozanimod and cladribine mean that, for the first time, people with progressive forms of MS have different treatment options. …

Премии победителей и резюме 32nd Ежегодный симпозиум Общества протеинов; Бостон, ОЭТ, июль 9-12, 2018.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Epigenetics-targeted drugs: current paradigms and future challenges.

Epigenetics governs a chromatin state regulatory system through five key mechanisms: DNA modification, histone modification, RNA modification, chromatin remodeling, and non-coding RNA regulation. These mechanisms and their associated enzymes convey genetic information independently of DNA base sequences, playing essential roles in organismal development and homeostasis. Conversely, disruptions in epigenetic landscapes critically influence the pathogenesis of various human diseases. This understanding has laid a robust theoretical groundwork for developing drugs that target epigenetics-modifyin

Совпадение в полном тексте источника
… quality of life and exhibits acceptable adverse events) Phase II — NCT03075826 Guadecitabine DNMT1 HCC Completed (high incidence of treatment-related adverse events) Phase II — NCT01752933 Guadecitabine DNMT1 AML Completed (exhibits comparable clinical response rates and safety) Phase II With or without Cladribine … acceptable adverse events) | Phase II | — | NCT03075826 Guadecitabine | DNMT1 | HCC | Completed (high incidence of treatment-related adverse events) | Phase II | — | NCT01752933 Guadecitabine | DNMT1 | AML | Completed (exhibits comparable clinical response rates and safety) | Phase II | With or without Cladribine …

:: 45th Ежегодное совещание Европейского общества по трансплантации крови и костного мозга: Врачи - сессия плаката.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.